Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 12, 2021 08:00 ET
|
Vincerx Pharma, Inc.
Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL...
Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting
November 04, 2021 09:01 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces $50 Million Private Placement
September 16, 2021 07:30 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
September 07, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
August 12, 2021 16:05 ET
|
Vincerx Pharma, Inc.
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in...
Vincerx Pharma Announces Inclusion in Russell 3000® and Microcap® Indexes
June 28, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
June 04, 2021 12:40 ET
|
Vincerx Pharma, Inc.
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021
June 04, 2021 08:00 ET
|
Vincerx Pharma, Inc.
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting Phase 1b study in MYC-Driven relapsed/refractory aggressive...
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
June 03, 2021 16:05 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...